CRL
FY2026 Q1 · Calendar Q2 2026
Charles River Laboratories International, Inc.
Charles River's Q1 FY2026 beat on both EPS ($2.06 vs $1.96, +5.1%) and revenue ($995.8M vs $977.5M, +1.9%) marks an incremental improvement from the 1.6% organic revenue decline in 2025. Management reaffirmed 2026 guidance and shifted tone from cautious to confident, citing net book-to-bill above 1.0, high-single-digit proposal volume growth, and a $300M cumulative cost-savings program targeting 120-150 bps of operating margin expansion. The strategic narrative now centers on NHP supply internalization (K.F. Cambodia, Noveprim), portfolio reshaping (CDMO and Cell Solutions divested, PathoQuest acquired), and AI/NAMs as long-term growth drivers. The market response was muted -- a 0.28% abnormal return on elevated volume -- suggesting investors are waiting for the September Investor Day to validate the Pathway to Purpose strategy. The stock trades at $233.59, modestly above the analyst…
EPS surprise+5.1%
Market move-0.0%
